新冠病毒变异株对感染或接种个体中总 CD4 和 CD8 T 细胞反应性的影响。
Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or vaccinated individuals.
机构信息
Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
Department of Internal Medicine and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa 16132, Italy.
出版信息
Cell Rep Med. 2021 Jul 20;2(7):100355. doi: 10.1016/j.xcrm.2021.100355. Epub 2021 Jul 2.
The emergence of SARS-CoV-2 variants with evidence of antibody escape highlight the importance of addressing whether the total CD4 and CD8 T cell recognition is also affected. Here, we compare SARS-CoV-2-specific CD4 and CD8 T cells against the B.1.1.7, B.1.351, P.1, and CAL.20C lineages in COVID-19 convalescents and in recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines. The total reactivity against SARS-CoV-2 variants is similar in terms of magnitude and frequency of response, with decreases in the 10%-22% range observed in some assay/VOC combinations. A total of 7% and 3% of previously identified CD4 and CD8 T cell epitopes, respectively, are affected by mutations in the various VOCs. Thus, the SARS-CoV-2 variants analyzed here do not significantly disrupt the total SARS-CoV-2 T cell reactivity; however, the decreases observed highlight the importance for active monitoring of T cell reactivity in the context of SARS-CoV-2 evolution.
具有抗体逃逸证据的 SARS-CoV-2 变异株的出现突显了需要解决的重要问题，即总 CD4 和 CD8 T 细胞识别是否也受到影响。在这里，我们比较了 COVID-19 恢复期患者和接受 Moderna（mRNA-1273）或辉瑞/生物科技（BNT162b2）COVID-19 疫苗接种者的 SARS-CoV-2 特异性 CD4 和 CD8 T 细胞对 B.1.1.7、B.1.351、P.1 和 CAL.20C 谱系的反应。就反应幅度和频率而言，针对 SARS-CoV-2 变异株的总反应性相似，在某些检测/VOC 组合中观察到 10%-22%的下降。在各种 VOC 中，分别有 7%和 3%的先前确定的 CD4 和 CD8 T 细胞表位受到突变的影响。因此，这里分析的 SARS-CoV-2 变异株并没有显著破坏总 SARS-CoV-2 T 细胞反应性；然而，观察到的下降强调了在 SARS-CoV-2 进化的背景下主动监测 T 细胞反应性的重要性。
Zotero 插件